Enanta Pharmaceuticals (ENTA) has just posted Q2 2026 results with revenue of US$17.2 million and a basic EPS loss of US$0.45, while trailing twelve month figures show revenue of US$69.2 million and a basic EPS loss of US$2.47. Over recent quarters the company has seen revenue move between US$14.9 million and US$18.6 million, with quarterly basic EPS losses ranging from roughly US$0.41 to US$1.06 and trailing twelve month net losses of US$62.0 million. For investors, the story this quarter is about how these steady top line numbers sit against ongoing losses and what that means for the path to healthier margins.
See our full analysis for Enanta Pharmaceuticals.With the headline figures set, the next step is to see how these results line up with the most common narratives around Enanta Pharmaceuticals, and where the numbers start to challenge those stories.
Curious how numbers become stories that shape markets? Explore Community Narratives
Losses Narrow On Trailing Basis
- Over the last twelve months, Enanta reported revenue of US$69.2 million and a net loss of US$62.0 million, compared with a loss of US$71.5 million on US$67.0 million of revenue at the prior trailing point.
- What stands out for the more optimistic view is that earnings have been improving at about 2.3% per year over five years, and the trailing twelve month loss narrowed by roughly US$9.6 million. This lines up with the idea of gradual progress even though net income is still negative.
Q2 Loss Smaller Than A Year Ago
- Q2 2026 net loss was US$13.1 million compared with Q2 2025 net loss of US$22.6 million, while revenue moved from US$14.9 million to US$17.2 million over the same periods.
- Bears worry about ongoing unprofitability with no forecast path to profit over the next three years. Yet the drop in quarterly loss of about US$9.5 million versus Q2 2025 and the shift from Q1 2025 losses of US$22.3 million to Q1 2026 losses of US$11.9 million show that, even with negative earnings, reported losses have been getting smaller across recent comparable quarters.
5.8x P/S Vs Higher Biotech Averages
- Enanta trades on a P/S of 5.8x, which is below the US biotechs industry average of 10.6x and the peer average of 12.4x.
- Critics highlight major risks such as substantial shareholder dilution over the last year and the expectation of continued losses. Those concerns sit alongside revenue that analysts expect to grow around 17.6% per year and a lower P/S multiple than peers, a combination that supports the idea that the stock is priced more cautiously despite the revenue growth profile.
For a broader view of how these numbers fit into the long term story, including risks and potential rewards, it can help to see how other investors are framing the company right now, then compare that with your own expectations for the pipeline and cash needs before making any decisions.Curious how numbers become stories that shape markets? Explore Community Narratives
Next Steps
Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Enanta Pharmaceuticals's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.
Given the mix of caution and optimism in the numbers and commentary, it makes sense to check the details yourself and decide where you stand. If you want a quick way to weigh the downside against the upside before reacting to the latest results, start by reviewing the 3 key rewards and 2 important warning signs.
Explore Alternatives
Enanta is still reporting consistent losses alongside shareholder dilution, with no analyst forecast of profitability over the next three years.
If you want stocks where balance sheets and earnings profiles look more resilient, start comparing ideas in the 67 resilient stocks with low risk scores to potentially reduce portfolio stress.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com